Søgeord (covid) valgt.
380 emner vises.
1
COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 BA.1/BA.2 lineages among adults and adolescents in a multicentre primary care study, Europe, December 2021 to June 2022
Charlotte Lanièce Delaunay, Iván Martínez-Baz, Noémie Sève, Lisa Domegan, Clara Mazagatos, Silke Buda, Adam Meijer, Irina Kislaya, Catalina Pascu, AnnaSara Carnahan, Beatrix Oroszi, Maja Ilić, Marine Maurel, Aryse Melo, Virginia Sandonis Martín, Camino Trobajo-Sanmartín, Vincent Enouf, Adele McKenna, Gloria Pérez-Gimeno, Luise Goerlitz, Marit de Lange, Ana Paula Rodrigues, Mihaela Lazar, Neus Latorre-Margalef, Gergő Túri, Jesús Castilla, Alessandra Falchi, Charlene Bennett, Virtudes Gallardo, Ralf Dürrwald, Dirk Eggink, Raquel Guiomar, Rodica Popescu, Maximilian Riess, Judit Krisztina Horváth, Itziar Casado, Mª del Carmen García, Mariëtte Hooiveld, Ausenda Machado, Sabrina Bacci, Marlena Kaczmarek, Esther Kissling and on behalf of the European Primary Care Vaccine Effectiveness Group
Eurosurveillance latest updates, 29.03.2024
Tilføjet 29.03.2024
BackgroundScarce European data in early 2021 suggested lower vaccine effectiveness (VE) against SARS-CoV-2 Omicron lineages than previous variants. AimWe aimed to estimate primary series (PS) and first booster VE against symptomatic BA.1/BA.2 infection and investigate potential biases. MethodsThis European test-negative multicentre study tested primary care patients with acute respiratory symptoms for SARS-CoV-2 in the BA.1/BA.2-dominant period. We estimated PS and booster VE among adults and adolescents (PS only) for all products combined and for Comirnaty alone, by time since vaccination, age and chronic condition. We investigated potential bias due to correlation between COVID-19 and influenza vaccination and explored effect modification and confounding by prior SARS-CoV-2 infection. ResultsAmong adults, PS VE was 37% (95% CI: 24–47%) overall and 60% (95% CI: 44–72%), 43% (95% CI: 26–55%) and 29% (95% CI: 13–43%)
Læs mere
2
Atypical age distribution and high disease severity in children with RSV infections during two irregular epidemic seasons throughout the COVID-19 pandemic, Germany, 2021 to 2023
Wei Cai, Sophie Köndgen, Kristin Tolksdorf, Ralf Dürrwald, Ekkehard Schuler, Barbara Biere, Brunhilde Schweiger, Luise Goerlitz, Walter Haas, Thorsten Wolff, Silke Buda and Janine Reiche
Eurosurveillance latest updates, 29.03.2024
Tilføjet 29.03.2024
BackgroundNon-pharmaceutical interventions (NPIs) during the COVID-19 pandemic affected respiratory syncytial virus (RSV) circulation worldwide. AimTo describe, for children aged
Læs mere
3
Interim Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19-Associated Hospitalization Among Adults Aged ≥18 Years with Immunocompromising Conditions - VISION Network, September 2023-February 2024
Morbidity and Mortality Weekly Report (MMWR), 29.03.2024
Tilføjet 29.03.2024
This report describes the effectiveness of the updated COVID-19 vaccine in preventing hospitalizations in adults with immunocompromising conditions.
Læs mere
4
New Data: Long COVID Cases Surge
Medscape Infectious Diseases, 28.03.2024
Tilføjet 28.03.2024
A post-winter rise in estimated long COVID cases may last well into 2024, experts said. Medscape Medical News
Læs mere
5
No Increased Stroke Risk After COVID-19 Bivalent Vaccine
Medscape Infectious Diseases, 28.03.2024
Tilføjet 28.03.2024
There is no increased risk for stroke during the 6 weeks following receipt of either brand of the COVID-19 bivalent vaccine, new research shows. Medscape Medical News
Læs mere
6
How COVID-19 Treatments Affect Patients With IBD
Medscape Infectious Diseases, 26.03.2024
Tilføjet 26.03.2024
Inflammatory bowel disease therapies for patients may need to be briefly halted during treatment for COVID-19, but it does not increase flares. Medscape Medical News
Læs mere
7
Severe Flu Confers Higher Risk for Neuro Disorders vs COVID
Medscape Infectious Diseases, 22.03.2024
Tilføjet 22.03.2024
Hospitalization for influenza raises the risk for future neurologic conditions more than hospitalization for COVID-19, the results of a large study showed. Medscape Medical News
Læs mere
8
Surveillance for Coccidioidomycosis, Histoplasmosis, and Blastomycosis During the COVID-19 Pandemic - United States, 2019-2021
Morbidity and Mortality Weekly Report (MMWR), 21.03.2024
Tilføjet 21.03.2024
This report describes trends in coccidioidomycosis, histoplasmosis, and blastomycosis cases during the COVID-19 pandemic.
Læs mere
9
Immunomodulators Do Not Affect COVID-19 Vaccine Efficacy
Medscape Infectious Diseases, 21.03.2024
Tilføjet 21.03.2024
A study suggested that immunomodulatory medications do not increase the risk for COVID-19 related hospitalizations in patients who have received the COVID-19 vaccine. Medscape Medical News
Læs mere
10
Getting Reluctant Patients to 'Yes' on COVID Vaccination
Medscape Infectious Diseases, 20.03.2024
Tilføjet 20.03.2024
Five useful tips for helping the vax-hesitant people get past their objections. Medscape Medical News
Læs mere
11
'Critical' to Catch Up on Measles Vaccinations to Stem Outbreaks, Says WHO
Medscape Infectious Diseases, 20.03.2024
Tilføjet 20.03.2024
Vaccinating children who missed their measles shots during the COVID-19 pandemic is critical, a senior World Health Organization official said on Tuesday, as outbreaks of... Reuters Health Information
Læs mere
12
After-Action review of the public health response of Slovenia to the COVID-19 pandemic
ECDC
ECDC COVID-19 updates, 20.03.2024
Tilføjet 20.03.2024
At the request of the Slovenian National Institute of Public Health (NIJZ), ECDC designed and facilitated an After-Action review (AAR), focusing on the response to the COVID-19 pandemic.
Læs mere
13
Reporting Protocol for integrated respiratory virus surveillance, version 1.5
ECDC
ECDC COVID-19 updates, 20.03.2024
Tilføjet 20.03.2024
This Reporting Protocol describes data collection for influenza, COVID-19, and other respiratory viruses (such as RSV or new viruses of public health concern) in the EU/EEA and wider WHO European Region. Data collection is integrated for most datasets in line with the operational considerations for respiratory virus surveillance in Europe.
Læs mere
14
Epilepsy Linked to Higher COVID Hospitalization, Death Rates
Medscape Infectious Diseases, 15.03.2024
Tilføjet 15.03.2024
Epilepsy was linked to a significantly increased the risk for hospitalization and death from COVID-19 early in the pandemic, while healthcare utilization rates declined. Medscape Medical News
Læs mere
15
Protocol for a COVID-19 vaccine effectiveness multi-country cohort study in the paediatric population aged 5–17-years using electronic health records in EU/EEA countries
ECDC
ECDC COVID-19 updates, 15.03.2024
Tilføjet 15.03.2024
This protocol describes the common methodology to be applied to established health data registries across seven participating EU/EEA Member States to estimate vaccine effectiveness for Coronavirus disease 2019 (COVID-19) in children and adolescents aged 5-17 years old.
Læs mere
16
Opinion: COVID, 4 Years on
Medscape Infectious Diseases, 15.03.2024
Tilføjet 15.03.2024
A quick update on some important new data Medscape
Læs mere
17
Five Keys to Helping Long-COVID Patients Recover
Medscape Infectious Diseases, 15.03.2024
Tilføjet 15.03.2024
Certain strategies have proven helpful for sufferers of long COVID as they slowly progress through recovery. Medscape Medical News
Læs mere
18
Notes from the Field: Surveillance for Multisystem Inflammatory Syndrome in Children - United States, 2023
Morbidity and Mortality Weekly Report (MMWR), 14.03.2024
Tilføjet 14.03.2024
This report describes changes in multisystem inflammatory syndrome cases among children since early in the COVID-19 pandemic.
Læs mere
19
COVID Virus Can Remain in the Body Over a Year
Medscape Infectious Diseases, 11.03.2024
Tilføjet 11.03.2024
Scientists found COVID antigens in the blood for up to 14 months after infection and in tissue samples for more than 2 years after infection. WebMD Health News
Læs mere
20
Projecting COVID-19 intensive care admissions for policy advice, the Netherlands, February 2020 to January 2021
Don Klinkenberg, Jantien Backer, Nicolette de Keizer and Jacco Wallinga
Eurosurveillance latest updates, 8.03.2024
Tilføjet 8.03.2024
BackgroundModel projections of coronavirus disease 2019 (COVID-19) incidence help policymakers about decisions to implement or lift control measures. During the pandemic, policymakers in the Netherlands were informed on a weekly basis with short-term projections of COVID-19 intensive care unit (ICU) admissions. AimWe aimed at developing a model on ICU admissions and updating a procedure for informing policymakers. MethodThe projections were produced using an age-structured transmission model. A consistent, incremental update procedure integrating all new surveillance and hospital data was conducted weekly. First, up-to-date estimates for most parameter values were obtained through re-analysis of all data sources. Then, estimates were made for changes in the age-specific contact rates in response to policy changes. Finally, a piecewise constant transmission rate was estimated by fitting the model to reported daily ICU admissions, with a changepoint analysis guided by Akaike\'s Information Criterion. ResultsThe model and update procedure allowed us to make weekly projections. Most 3-week prediction intervals were accurate in covering the later observed numbers of ICU admissions. When projections were too high in March and August 2020 or too low in November 2020, the estimated effectiveness of the policy changes was adequately adapted in the changepoint analysis based on the natural accumulation of incoming data. ConclusionThe model incorporates basic epidemiological principles and most model parameters were estimated per data source. Therefore, it had potential to be adapted to a more complex epidemiological situation with the rise of new variants and the start of vaccination.
Læs mere
21
Opinion: Long COVID and Cognitive Deficits
Medscape Infectious Diseases, 7.03.2024
Tilføjet 7.03.2024
What we\'re learning from two new, large-population prospective assessments. Medscape
Læs mere
22
Risk for Rheumatic Disease May Rise After COVID
Medscape Infectious Diseases, 7.03.2024
Tilføjet 7.03.2024
While previous studies had identified a link between COVID-19 infection and greater risk for autoimmune disease, a new study is perhaps the largest and most robust to date to show an association. MDedge News
Læs mere
23
Mild COVID and Risk for Neuro, Psych Disorders: New Data
Medscape Infectious Diseases, 5.03.2024
Tilføjet 5.03.2024
A new study confirms earlier reports of increased risks for psychiatric and neurologic disorders after severe COVID but found no association between risk and mild illness. Medscape Medical News
Læs mere
24
Interim Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalization Among Immunocompetent Adults Aged ≥18 Years - VISION and IVY Networks, September 2023-January 2024
Morbidity and Mortality Weekly Report (MMWR), 29.02.2024
Tilføjet 29.02.2024
This report describes vaccine effectiveness for the updated 2023-24 COVID-19 vaccine.
Læs mere
25
Cognitive Deficits Post-COVID Range From 3-9 IQ Point Loss
Medscape Infectious Diseases, 29.02.2024
Tilføjet 29.02.2024
COVID-19–related cognitive deficits in severe cases were equivalent to a 9-point drop in IQ, new data show, with most deficits in memory, reasoning, and executive function. Medscape Medical News
Læs mere
26
Biological Sex Differences: Key to Understanding Long COVID?
Medscape Infectious Diseases, 28.02.2024
Tilføjet 28.02.2024
New evidence continues to suggest a complicated link between sex hormone fluctuation and immune dysfunction in long COVID. Medscape Medical News
Læs mere
27
Opinion: Toward Solving the Long COVID Puzzle
Medscape Infectious Diseases, 23.02.2024
Tilføjet 23.02.2024
In recent days, there were several important new reports that help explain the pathophysiology of long COVID. The new findings are summarized here. Medscape Medical News
Læs mere
28
Studie med 99 mio. deltagere: Alvorlige bivirkninger efter covid-19 vacciner er sjældne
Statens Serum Institut, 23.02.2024
Tilføjet 23.02.2024
Verdens største studie af covid-19 vaccinernes sikkerhed bekræfter, at alvorlige bivirkninger efter vaccination sjældne.
Læs mere
29
Application of the screening method for estimating COVID-19 vaccine effectiveness using routine surveillance data: Germany’s experience during the COVID-19 pandemic, July 2021 to March 2023
Nita Perumal, Viktoria Schönfeld and Ole Wichmann
Eurosurveillance latest updates, 23.02.2024
Tilføjet 23.02.2024
The screening method represents a simple, quick, and practical tool for estimating vaccine effectiveness (VE) using routine disease surveillance and vaccine coverage data, even if these data cannot be linked. In Germany, where notification data, laboratory testing data, and vaccine coverage data cannot be linked due to strict data protection requirements, the screening method was used to assess COVID-19 VE continuously between July 2021 and March 2023. During this period, when Delta and Omicron variants circulated, VE estimates were produced in real-time for different age groups and clinical outcomes. Here we describe the country’s overall positive experience using the screening method, including its strengths and limitations, and provide practical guidance regarding a few issues, such as case definition stringency, testing behaviour, and data stratification, that require careful consideration during data analysis and the interpretation of the results.
Læs mere
30
Wastewater-based reproduction numbers and projections of COVID-19 cases in three areas in Japan, November 2021 to December 2022
Shogo Miyazawa, Ting Sam Wong, Genta Ito, Ryo Iwamoto, Kozo Watanabe, Michiel van Boven, Jacco Wallinga and Fuminari Miura
Eurosurveillance latest updates, 23.02.2024
Tilføjet 23.02.2024
BackgroundWastewater surveillance has expanded globally as a means to monitor spread of infectious diseases. An inherent challenge is substantial noise and bias in wastewater data because of the sampling and quantification process, limiting the applicability of wastewater surveillance as a monitoring tool. AimTo present an analytical framework for capturing the growth trend of circulating infections from wastewater data and conducting scenario analyses to guide policy decisions. MethodsWe developed a mathematical model for translating the observed SARS-CoV-2 viral load in wastewater into effective reproduction numbers. We used an extended Kalman filter to infer underlying transmissions by smoothing out observational noise. We also illustrated the impact of different countermeasures such as expanded vaccinations and non-pharmaceutical interventions on the projected number of cases using three study areas in Japan during 2021–22 as an example. ResultsObserved notified cases were matched with the range of cases estimated by our approach with wastewater data only, across different study areas and virus quantification methods, especially when the disease prevalence was high. Estimated reproduction numbers derived from wastewater data were consistent with notification-based reproduction numbers. Our projections showed that a 10–20% increase in vaccination coverage or a 10% reduction in contact rate may suffice to initiate a declining trend in study areas. ConclusionOur study demonstrates how wastewater data can be used to track reproduction numbers and perform scenario modelling to inform policy decisions. The proposed framework complements conventional clinical surveillance, especially when reliable and timely epidemiological data are not available.
Læs mere
31
Notes from the Field: Reemergence of Mycoplasma pneumoniae Infections in Children and Adolescents After the COVID-19 Pandemic, United States, 2018-2024
Morbidity and Mortality Weekly Report (MMWR), 22.02.2024
Tilføjet 22.02.2024
This report describes an increase in Mycoplasma pneumoniae, a common cause of respiratory illness, beginning in fall 2023.
Læs mere
32
Italy Spent Around 45% Of EU COVID Recovery Cash Received So Far, Report Shows
Medscape Infectious Diseases, 22.02.2024
Tilføjet 22.02.2024
Italy has spent around 45% of the almost 102 billion euros ($110.7 billion) it has received so far from European Union COVID-19 recovery funds, short of a target set in... Reuters Health Information
Læs mere
33
Covid-19-smitte giver flere neurologiske diagnoser
Statens Serum Institut, 22.02.2024
Tilføjet 22.02.2024
I den brede danske befolkning blev der diagnosticeret flere neurologiske lidelser efter smitte med covid-19. Det viser en ny stor undersøgelse fra Statens Serum Institut, hvor der indgik knap 1,8 mio smittede danskere.
Læs mere
34
Study IDs Immune Abnormality Possibly Causing Long COVID
Medscape Infectious Diseases, 22.02.2024
Tilføjet 22.02.2024
Dysfunctional complement system proteins could explain chronic inflammation, fatigue, and other long COVID symptoms, leading to new treatments. Medscape Medical News
Læs mere
35
What to Know About COVID Rebound
Medscape Infectious Diseases, 22.02.2024
Tilføjet 22.02.2024
The CDC\'s Pragna Patel, MD, MPH, and Dallas Smith, PharmD, answer common questions on COVID-19 rebound cases and antiviral treatment. CDC Expert Commentary
Læs mere
36
Bias in vaccine effectiveness studies of clinically severe outcomes that are measured with low specificity: the example of COVID-19-related hospitalisation
Christian Holm Hansen
Eurosurveillance latest updates, 16.02.2024
Tilføjet 16.02.2024
Many vaccine effectiveness (VE) analyses of severe disease outcomes such as hospitalisation and death include ‘false’ cases that are not actually caused by the infection or disease under study. While the inclusion of such false cases inflate outcome rates in both vaccinated and unvaccinated populations, it is less obvious how they affect estimates of VE. Illustrating the main points through simple examples, this article shows how VE is underestimated when false cases are included as outcomes. Depending how the outcome indicator is defined, estimates of VE against severe disease outcomes, whose definition allows for the inclusion of false cases, will be biased downwards and may in certain circumstances approximate the same level as the VE against infection. The bias is particularly pronounced for vaccines that offer high levels of protection against severe disease outcomes but poor protection against infection. Analysing outcomes that are measured with low sensitivity generally does not cause bias in VE studies; defining outcome indicators that minimise the number of false cases rather than the number of missed cases is preferable in VE studies.
Læs mere
37
Epidemiology of reported cases of leptospirosis in the EU/EEA, 2010 to 2021
Julien Beauté, Francesco Innocenti, Aristos Aristodimou, Michaela Špačková, Caroline Eves, Natalia Kerbo, Ruska Rimhanen-Finne, Mathieu Picardeau, Mirko Faber, Georgios Dougas, Anna Margrét Halldórsdóttir, Sarah Jackson, Viktorija Leitēna, Anne Vergison, Maria Louise Borg, Roan Pijnacker, Małgorzata Sadkowska-Todys, João Vieira Martins, Lavinia Cipriana Rusu, Eva Grilc, Rosa M Estévez-Reboredo, Taina Niskanen and Therese Westrell
Eurosurveillance latest updates, 16.02.2024
Tilføjet 16.02.2024
BackgroundLeptospirosis is a zoonotic disease caused by bacteria of the genus Leptospira. Humans are infected by exposure to animal urine or urine-contaminated environments. Although disease incidence is lower in Europe compared with tropical regions, there have been reports of an increase in leptospirosis cases since the 2000s in some European countries. AimWe aimed to describe the epidemiology of reported cases of leptospirosis in the European Union/European Economic Area (EU/EEA) during 2010−2021 and to identify potential changes in epidemiological patterns. MethodsWe ran a descriptive analysis of leptospirosis cases reported by EU/EEA countries to the European Centre for Disease Prevention and Control with disease during 2010−2021. We also analysed trends at EU/EEA and national level. ResultsDuring 2010–2021, 23 countries reported 12,180 confirmed leptospirosis cases corresponding to a mean annual notification rate of 0.24 cases per 100,000 population. Five countries (France, Germany, the Netherlands, Portugal and Romania) accounted for 79% of all reported cases. The highest notification rate was observed in Slovenia with 0.82 cases per 100,000 population. Overall, the notification rate increased by 5.0% per year from 2010 to 2021 (95% CI: 1.2–8.8%), although trends differed across countries. ConclusionThe notification rate of leptospirosis at EU/EEA level increased during 2010−2021 despite including the first 2 years of the COVID-19 pandemic and associated changes in population behaviours. Studies at (sub)national level would help broaden the understanding of differences at country-level and specificities in terms of exposure to Leptospira, as well as biases in diagnosis and reporting.
Læs mere
38
2023/24 mid-season influenza and Omicron XBB.1.5 vaccine effectiveness estimates from the Canadian Sentinel Practitioner Surveillance Network (SPSN)
Danuta M Skowronski, Yuping Zhan, Samantha E Kaweski, Suzana Sabaiduc, Ayisha Khalid, Romy Olsha, Sara Carazo, James A Dickinson, Richard G Mather, Hugues Charest, Agatha N Jassem, Inès Levade, Maan Hasso, Nathan Zelyas, Ruimin Gao and Nathalie Bastien
Eurosurveillance latest updates, 16.02.2024
Tilføjet 16.02.2024
The Canadian Sentinel Practitioner Surveillance Network reports mid-season 2023/24 influenza vaccine effectiveness (VE) of 63% (95% CI: 51–72) against influenza A(H1N1)pdm09, lower for clade 5a.2a.1 (56%; 95% CI: 33–71) than clade 5a.2a (67%; 95% CI: 48–80), and lowest against influenza A(H3N2) (40%; 95% CI: 5–61). The Omicron XBB.1.5 vaccine protected comparably well, with VE of 47% (95% CI: 21–65) against medically attended COVID-19, higher among people reporting a prior confirmed SARS-CoV-2 infection at 67% (95% CI: 28–85).
Læs mere
39
Notes from the Field: Long COVID Prevalence Among Adults - United States, 2022
Morbidity and Mortality Weekly Report (MMWR), 16.02.2024
Tilføjet 16.02.2024
This report describes the prevalence of adults who reported ever experiencing Long COVID.
Læs mere
40
Laboratory Support for influenza and SARS-CoV-2 for Europe: AURORAE
ECDC
ECDC COVID-19 updates, 15.02.2024
Tilføjet 15.02.2024
AURORAE provides laboratory support for surveillance, preparedness and response to COVID-19 and influenza and strengthens the capacity for genomic epidemiology and public health bioinformatics through interdisciplinary training, which is crucial for response during a pandemic or unexpected major public health events.
Læs mere
41
Virus and Booster Apathy Could Be Fueling Long COVID
Medscape Infectious Diseases, 14.02.2024
Tilføjet 14.02.2024
\'Stupidest thing I\'ve ever done\': A lack of urgency surrounding virus spread and boosters may be triggering additional long COVID cases. Medscape Medical News
Læs mere
42
SARS-CoV-2 a Possible Trigger for Achalasia
Medscape Infectious Diseases, 13.02.2024
Tilføjet 13.02.2024
Researchers described cases of rapidly developing achalasia following COVID-19 and confirmed SARS-CoV-2 antigen in esophageal muscle tissue. Medscape Medical News
Læs mere
43
Protocol for a COVID-19 vaccine effectiveness estimation using health data registries, VEBIS multi-country study - Version 2.0
ECDC
ECDC COVID-19 updates, 13.02.2024
Tilføjet 13.02.2024
This protocol presents a common updated methodology to estimate vaccine effectiveness (VE) for COVID-19, using established health data registries in participating European Union and European Economic Area (EU/EEA) countries.
Læs mere
44
Communicable disease threats report, 4-10 February 2024, week 6
ECDC
ECDC Communicable Disease Threats Report, 9.02.2024
Tilføjet 9.02.2024
This issue of the ECDC Communicable Disease Threats Report (CDTR) the period 4-10 February 2024 and includes updates on avian influenza, measles, MERS-CoV, COVID-19, swine influenza, respiratory virus epidemiology, Western equine encephalitis, Hepatitis E, and the Chinese New Year.
Læs mere
45
Communicable disease threats report, 4-10 February 2024, week 6
ECDC
ECDC COVID-19 updates, 9.02.2024
Tilføjet 9.02.2024
This issue of the ECDC Communicable Disease Threats Report (CDTR) the period 4-10 February 2024 and includes updates on avian influenza, measles, MERS-CoV, COVID-19, swine influenza, respiratory virus epidemiology, Western equine encephalitis, Hepatitis E, and the Chinese New Year.
Læs mere
46
New Evidence Suggests Long COVID Could Be a Brain Injury
Medscape Infectious Diseases, 8.02.2024
Tilføjet 8.02.2024
Long-COVID sufferers of brain fog and memory loss exhibit elevated biomarkers consistent with brain injury. Medscape Medical News
Læs mere
47
De første covid-19-vacciner gav ikke flere bivirkninger
Statens Serum Institut, 8.02.2024
Tilføjet 8.02.2024
Særligt på sociale medier har der gennem længere tid floreret en myte om, at de første små partier af covid-19 vaccinen ikke havde samme kvalitet som de senere større partier, og at de derfor førte til langt flere bivirkninger. Denne myte punkteres nu i en ny stor undersøgelse fra Statens Serum Institut.
Læs mere
48
Core protocol for ECDC studies of COVID-19 vaccine effectiveness against hospitalisation with Severe Acute Respiratory Infection, laboratory-confirmed with SARS-CoV-2 or with seasonal influenza - Version 3.0
ECDC
ECDC COVID-19 updates, 6.02.2024
Tilføjet 6.02.2024
This core protocol for ECDC studies of VE against hospitalisation with SARI laboratory-confirmed with SARS-CoV-2 or with influenza, version 3.0, represents an update to the main elements for a multi-country hospital-based study of COVID-19 vaccine effectiveness in patients hospitalised with SARI, initially published as version 1.0 [5], updated to version 2.0 [6].
Læs mere
49
Data on COVID-19 vaccination in the EU/EEA
ECDC
ECDC COVID-19 updates, 2.02.2024
Tilføjet 2.02.2024
This downloadable data file contains information on COVID-19 vaccination in the EU/EEA since September 2023.
Læs mere
50
Early Estimates of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Attributable to Co-Circulating Omicron Variants Among Immunocompetent Adults - Increasing Community Access to Testing Program, United States, September 2023-January 2024
Morbidity and Mortality Weekly Report (MMWR), 2.02.2024
Tilføjet 2.02.2024
This report describes vaccine effectiveness for the updated COVID-19 vaccine in preventing symptomatic SARS-CoV-2 infection.
Læs mere